Healthcare / Drug Manufacturers - Specialty & GenericKSE
$5470.00
-60.00 (-1.08%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-13.0B · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$130.8B
P/E
683.8x
↑EV/EBITDA
13.6x
↑ROE
0.1%
↓Gross Margin
38.7%
↓Debt/Equity
0.87
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+10.4%
FCF CAGR
—
FCF margin
-12.9%
FCF / Net income
-187.38x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $264.10B · net income $182.3M · FCF $-34.16B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $264.10B | $264.10B | $238.56B | $216.36B | $196.26B |
| Net Income | $182.3M | $182.3M | $4.64B | $2.97B | $610.6M |
| EBITDA | $17.94B | $17.94B | $21.60B | $17.27B | $12.99B |
| EPS | 8.00 | 8.00 | 194.00 | 124.00 | 26.00 |
| Gross Margin | 38.7% | 38.7% | 37.4% | 29.2% | 22.6% |
| Operating Margin | 1.3% | 1.3% | 4.4% | 2.6% | 0.7% |
| Net Margin | 0.1% | 0.1% | 1.9% | 1.4% | 0.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.87 | 0.87 | 0.63 | 0.53 | 0.45 |
| Current Ratio | 0.94 | 0.94 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-34.16B | $-34.16B | $-13.03B | $-6.03B | $-3.06B |
| Returns | |||||
| ROE | 0.1% | 0.1% | 3.2% | 2.1% | 0.4% |
| Valuation | |||||
| P/E | 683.75 | 683.75 | 35.57 | 65.32 | 348.08 |
| EV/EBITDA | 13.60 | 13.60 | 11.68 | 15.39 | 20.84 |
| P/B | 0.86 | 0.86 | 1.13 | 1.35 | 1.48 |
| Growth & Yield | |||||
| Revenue Growth | 10.7% | 10.7% | 10.3% | 10.2% | — |
| EPS Growth | -95.9% | -95.9% | 56.5% | 376.9% | — |
| Dividend Yield | 0.9% | 0.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
292.9%
EPS terminal req.
$485.37
Spread vs growth
-388.8%
5Y implied EPS CAGR
136.1%
EPS terminal req.
$587.30
Spread vs growth
-232.0%
10Y implied EPS CAGR
61.2%
EPS terminal req.
$945.85
Spread vs growth
-157.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+7.3%
Start / end P/E
26.5x → 683.8x
EPS bridge
194.00 → 8.00
Residual
-2378.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.